Inovio Pharmaceuticals, Inc. — Q2 2013 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2013. Inovio is a clinical-stage biotechnology company developing DNA vaccines and immune therapies, including its SynCon technology and electroporation delivery systems. It had no approved human products and reported no product-sales revenue.
Financial performance and liquidity
- Revenue: Q2 revenue was $786,000, up from $436,000 in Q2 2012. Six-month revenue was $2.24 million, compared with $2.13 million. Revenue came mainly from grants, government contracts, license fees and milestones.
- Expenses and losses: Q2 R&D expense was $4.41 million and G&A was $3.05 million. Operating loss was $5.67 million, versus $6.79 million a year earlier. Net loss attributable to Inovio was $10.85 million, or $0.06 per share, compared with $4.13 million, or $0.03 per share. For the first six months, attributable net loss was $19.70 million, or $0.12 per share, versus $12.39 million, or $0.09 per share.
- Margins: Gross margin is not meaningful for this development-stage business; the filing reports no product sales or product cost of sales.
- Cash flow: First-half operating cash use was $10.55 million, investing cash use was $4.31 million, and financing provided $19.57 million. Cash and cash equivalents ended the period at $10.35 million.
- Liquidity: Cash plus short-term investments totaled $23.46 million; working capital was $6.5 million. Management said available cash and short-term investments were expected to fund planned working-capital requirements through Q1 2015, with outside financing needed thereafter.
- Balance sheet and debt: Total assets were $50.99 million and total liabilities were $21.32 million at June 30. The balance sheet shows no interest-bearing debt line; the filing does not provide a separate debt balance. Current liabilities included a $13.45 million warrant liability, up from $2.86 million at year-end.
Changes versus the prior comparable period
- Q2 revenue increased by $350,000, principally reflecting higher grant revenue, including NIAID and PATH-related revenue.
- First-half R&D expense rose to $9.53 million from $8.57 million, including higher HPV-003 clinical costs and compensation; first-half G&A increased to $6.02 million from $5.18 million, partly due to $316,000 of warrant-issuance transaction costs.
- Warrant revaluation was a major source of earnings volatility: it produced a $3.20 million Q2 expense and $4.63 million first-half expense in 2013, compared with gains in the 2012 comparable periods. Inovio also recorded a first-half $2.87 million loss on its investment in affiliated entity VGX International.
- Cash and short-term investments increased from $13.68 million at December 31, 2012, mainly due to equity financing and ATM sales. Working capital declined from $7.6 million, largely because of the increase in the warrant liability.
Outlook, commentary and risks
- In March 2013, Inovio raised approximately $14.0 million net in an underwritten offering of 27.4 million shares and warrants for up to 13.7 million shares. First-half ATM sales generated $5.6 million net from 8.2 million shares.
- After quarter-end, the company sold 4.25 million ATM shares for $6.1 million net and reported exercise of warrants covering 5.27 million shares for $5.3 million in proceeds.
- Management expected substantial future operating losses and continued reliance on external financing. There is no assurance of profitability or that additional capital will be available on acceptable terms; further equity financing could dilute shareholders.
- In March, collaborator ChronTech reported that its Phase II study of an earlier-generation HCV vaccine did not show statistically significant efficacy over the drug regimen alone. Inovio said it had ceased activities in that collaboration and expected VGX International to launch a Phase I study of Inovio’s multi-antigen HCV vaccine by year-end 2013.
- Inovio entered a ten-year San Diego office and R&D lease, expected to commence in Q4 2013, with monthly base rent ranging from zero to $82,945, plus operating expenses and a management fee.
- Key risks include clinical and regulatory uncertainty, manufacturing and collaboration dependence, reliance on grants and a limited number of revenue sources, and the need for continuing financing. Management reported effective disclosure controls and no material change in internal control over financial reporting during the quarter. Legal proceedings were reported as not applicable.
Investor verification points
- Confirm cash burn and the assumptions behind management’s stated runway through Q1 2015, including financing needs beyond that date.
- Track warrant-liability remeasurement and potential share dilution; the liability uses Level 3 valuation inputs and is sensitive to assumptions and share price.
- Verify HCV program progress and other clinical results, timelines, and regulatory developments; all human product candidates remained in R&D.
- Assess the sustainability and concentration of grant, government-contract and collaboration revenue, including future funding and performance obligations.
- Review subsequent ATM sales and warrant exercises, the share count impact, and the costs and commitments of the new lease.